Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

65 recalls, newest first

Class III · Low risk

treatNOW ABILIFY

Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Terminated Labeling / mix-up Otsuka Pharmaceutical Development & Commercialization, Inc. D-0018-2019
Class III · Low risk

treatNOW ABILIFY

Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Terminated Labeling / mix-up Otsuka Pharmaceutical Development & Commercialization, Inc. D-0017-2019
Class I · High risk

robaxin-750

Labeling: Incorrect Instructions: Dosage information on the immediate container label incorrectly states "Two to four tablets four times daily." rather than the correct dosage of "Two tablets three times daily."

Terminated Labeling / mix-up Endo Pharmaceuticals, Inc. NDC 52244-449-10 D-0009-2019
Class I · High risk

Hydrochlorothiazide Tablets USP

Product Mix-Up: customer complaint that a sealed bottle labeled as Hydrochlorothiazide Tablets USP 12.5 mg contained only Spironolactone Tablets USP 25 mg.

Terminated Labeling / mix-up Accord Healthcare, Inc. NDC 16729-182-01 D-1206-2018
Class III · Low risk

Oxycodone and Acetaminophen Tablets

Labeling: Incorrect or Missing Lot and/or Exp Date: Lot FG10517 is mislabeled on the primary container with Lot FG01517, shipper labels and invoices contain the correct lot number of FG10517.

Terminated Labeling / mix-up Mayne Pharma Inc NDC 68308-841-01 D-1129-2018
Class I · High risk

Montelukast Sodium Tablets 10 mg

Labeling: Label Mix-Up - One lot labeled Montelukast Sodium Tablets 10 mg tablets may contain 90 tablets of Losartan Potassium 50 mg.

Ongoing Labeling / mix-up Hetero Labs Limited Unit V NDC 31722-726-30 D-0081-2019
Class III · Low risk

Testosterone 200 mg Pellet

Labeling: Incorrect or Missing Lot and/or Exp Date: Incorrect expiration date on label

Terminated Labeling / mix-up Right Value Drug Stores, Inc. D-1047-2018
Class III · Low risk

Diazepam Rectal Gel

Labeling: Incorrect or Missing Lot and/or Exp Date: Product distributed without a lot number or expiration date on the outer carton.

Terminated Labeling / mix-up Valeant Pharmaceuticals North America LLC NDC 68682-650-20 D-1041-2018
Class I · High risk

Neostigmine Methylsulfate Injection Solution

Labeling: Label Error on Declared Strength: syringes of Neostigmine Methylsulfate 1 mg per mL, 5 mg per 5 mL may be incorrectly labeled as Neostigmine Methylsulfate 1 mg per mL, 3 mg per 3 mL.

Terminated Labeling / mix-up Fagron Compounding Services LLC dba Fagron Sterile Services NDC 71266-2003-01 D-0911-2018
Class I · High risk

Neostigmine Methylsulfate Injection Solution

Labeling: Label Error on Declared Strength: syringes of Neostigmine Methylsulfate 1 mg per mL, 5 mg per 5 mL may be incorrectly labeled as Neostigmine Methylsulfate 1 mg per mL, 3 mg per 3 mL.

Terminated Labeling / mix-up Fagron Compounding Services LLC dba Fagron Sterile Services NDC 71266-2003-02 D-0910-2018
Class III · Low risk

Equate ClearLAX

Labeling: Not Elsewhere Classified - A private label distributor noted unfiled NDC numbers on EQ ClearLax Polyethylene Glycol 3350 NF Powder Solution of various sizes.

Terminated Labeling / mix-up Lupin Somerset NDC 49035-312-07 D-0907-2018
Class III · Low risk

Riomet (metformin hydrochloride oral solution)

Labeling: Not Elsewhere Classified: Sun Pharma has decided to initiate this recall in response to identified labeling discrepancies in the patient literature.

Terminated Labeling / mix-up Sun Pharmaceutical Industries, Inc. NDC 10631-206-02 D-0818-2018
Class II · Moderate risk

Acetaminophen 300 mg with Codeine Phosphate 30 mg tablets

Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Terminated Labeling / mix-up Prescript Pharmaceuticals, Inc. D-0809-2018
Class II · Moderate risk

Clindamycin 300 mg capsules

Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Terminated Labeling / mix-up Prescript Pharmaceuticals, Inc. D-0808-2018
Class II · Moderate risk

Chlorhexidine 0.12% liquid

Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Terminated Labeling / mix-up Prescript Pharmaceuticals, Inc. D-0807-2018
Class II · Moderate risk

Acetaminophen 300 mg with Codeine Phosphate 30 mg tablets

Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Terminated Labeling / mix-up Prescript Pharmaceuticals, Inc. D-0806-2018
Class II · Moderate risk

Clindamycin 150 mg capsules

Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Terminated Labeling / mix-up Prescript Pharmaceuticals, Inc. D-0805-2018

Recalls by year